Skip to Main Content
Contribute Try STAT+ Today

More and more children are developing food allergies — and biotech companies are springing up to take advantage of the demand for treatments.

First on the scene, when parents and, eventually, allergists began to notice the increase in children’s food allergies, was Aimmune Therapeutics. The company was founded to prevent severe allergic reactions from happening, rather than react to them with epinephrine injections. In January 2020, just under a decade after its start, Aimmune’s oral immunotherapy became the first Food and Drug Administration-approved peanut allergy treatment.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment